Capital
Nanochon has closed another oversubscribed round, bringing in new capital and increasing the total amount raised to $4.1M. This round was led by Ecphora Capital and cultivate (MD), with significant contributions from the UVA Seed Fund and the new investor TEDCO. Many of our existing investors also participated, and we were pleased to welcome new investors. This funding will help propel us through our first in-human study in Canada, initiate additional R&D on our surgical instrument toolset, and allow us to begin preparations for our pivotal study, which we plan to initiate in Q1 2027.
We plan to open up our $20M Series A in Q3 2026, which will support our North American RCT and prepare us for FDA approval.
Clinical
Nanochon is excited to announce that we have officially initiated our first-in-human safety study in British Columbia. We are actively enrolling study participants after receiving hospital ethics approval and performing the site initiation visit. We look forward to keeping you up to date on enrollment and progress throughout the 12-month trial.
Alongside the clinical project, Nanochon has initiated additional goat studies to fully prepare the RCT IDE submission package for the FDA and, potentially, expand the indication language in a PMA filing down the road, specifically regarding the device’s biological effects on tissue regeneration and tissue quality.
R&D work also continues to refine our surgical tools, packaging, and device offerings in preparation for the launch of the pivotal study.
Outreach
This spring, Nanochon will have a strong presence across the industry’s leading conferences, providing opportunities to connect with colleagues and advance conversations at the forefront of innovation, including:
- Additive Manufacturing Strategies 2026 Conference: Feb 25th, New York
- 2026 CG Musculoskeletal Conference: Mar 1st, New Orleans
- American Academy of Orthopaedic Surgeons 2026 Annual Meeting: March 2nd-6th, New Orleans
- LSI USA ‘26: March 16th-20th, San Diego
- Maryland MedTech Summit: March 23rd-26th, Baltimore